INAB Stock Summary and Trading Ideas (In8bio | NASDAQ:INAB)

IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.

In8bio trades on the NASDAQ stock market under the symbol INAB.

As of April 15, 2026, INAB stock price climbed to $1.39 with 51,755 million shares trading.

INAB has a beta of 1.27, meaning it tends to be more sensitive to market movements. INAB has a correlation of 0.02 to the broad based SPY ETF.

INAB has a market cap of $13.69 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, INAB traded as high as $118.50 and as low as $1.17.

The top ETF exchange traded funds that INAB belongs to (by Net Assets): VXF, VTI.

INAB has underperformed the market in the last year with a price return of -70.9% while the SPY ETF gained +31.2%. INAB has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -37.1% and -6.1%, respectively, while the SPY returned +1.6% and +7.6%, respectively.

INAB support price is $1.29 and resistance is $1.47 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that INAB shares will trade within this expected range on the day.